

SUPPORT FOR THE AMENDMENTS

Applicant has amended Claim 1 to recite "wherein said material comprises at least one member selected from the group consisting of blood plasma, a blood plasma concentrate, and mixtures thereof." Support for this amendment can be found in Claim 40, as previously presented. Applicant has also added new Claims 42-66. Support for new Claims 42, 43, 47, 48, 52, 53, 57, 58, 62, and 63 can also be found in Claim 40, as previously presented. Support for new Claims 44, 45, 49, 50, 54, 55, 59, 60, 64, and 65 can be found on page 16, lines 15-19, of the specification. Support for new Claims 46, 51, 56, 61, and 66 can be found on page 21, lines 18-20, of the specification.

No new matter has been added. Claims 1-7, 9-13, 42-66 are pending in this application.

REMARKS/ARGUMENTS

At the outset, Applicant wishes to thank Examiner Kim for indicating that Claim 40 was only objected to as being dependent on a rejected base claim and would be allowable if rewritten in independent form. Applicant submits that, in view of the present amendments, all of the pending claims are now allowable.

The rejection of Claims 1, 5, 7, 9, 14, 15, 17, 18, 22, and 41 under 35 U.S.C. §103(a) in view of U.S. Patent No. 5,435,155 (Paradis) in view of U.S. Patent No. 4,156,645 (Bray); the rejection of Claims 10-13, 24 and 25 under 35 U.S.C. §103(a) in view of Paradis and Bray and further in view of U.S. Patent No. 5,966,966 (Botsaris et al); the rejection of Claims 1-4, 7, 14-19, and 22 under 35 U.S.C. §103(a) in view of WO 92/20420 in view of Paradis and Bray; and the rejection of Claims 6, 20, and 21 under 35 U.S.C. §103(a) in view of WO 92/20420 in view of Paradis and Bray and further in view of U.S. Patent No. 4,479,989 (Mahal) have all been obviated by appropriate amendment. First, as the Examiner will note,

Applicant has canceled Claims 14-22, 24, 25, and 41. Second, Applicant has amended Claim 1 to recite "wherein said material comprises at least one member selected from the group consisting of blood plasma, a blood plasma concentrate, and mixtures thereof." Applicant submits that Claim 1 and the claims dependent thereon are patentable over these cited references for the same reasons that Claim 40 was not rejected in view of these references.


Accordingly, these rejections should be withdrawn.

The rejection of Claims 14-22, 24, and 25 under 35 U.S.C. §112, second paragraph, has also been obviated by appropriate amendment. As noted above, these claims have been canceled. Again, the rejection should be withdrawn.

Applicant submits that the present application is now in condition for allowance, and early notification of such action is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Stephen G. Baxter, Ph.D.
Attorney of Record
Registration No. 32,884

Customer Number

22850

Tel: (703) 413-3000
Fax: (703) 413-2220
(OSMMN 08/03)